Massachusetts Financial Services Co. MA Raises Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Massachusetts Financial Services Co. MA grew its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 19.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 171,856 shares of the company’s stock after acquiring an additional 28,333 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Voyager Therapeutics were worth $1,005,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. Armistice Capital LLC raised its stake in Voyager Therapeutics by 11.3% during the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after purchasing an additional 528,000 shares during the period. Vanguard Group Inc. raised its position in shares of Voyager Therapeutics by 27.8% during the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock valued at $30,087,000 after buying an additional 702,030 shares during the last quarter. Farallon Capital Management LLC lifted its holdings in shares of Voyager Therapeutics by 77.4% in the first quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock worth $21,339,000 after buying an additional 1,000,000 shares in the last quarter. Great Point Partners LLC bought a new position in shares of Voyager Therapeutics during the second quarter worth $12,668,000. Finally, Price T Rowe Associates Inc. MD grew its stake in Voyager Therapeutics by 3.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company’s stock valued at $9,702,000 after acquiring an additional 37,144 shares in the last quarter. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Stock Up 1.9 %

NASDAQ VYGR opened at $5.78 on Thursday. Voyager Therapeutics, Inc. has a 52 week low of $5.19 and a 52 week high of $11.72. The firm has a market capitalization of $315.76 million, a price-to-earnings ratio of 7.99 and a beta of 0.89. The company has a fifty day moving average of $6.52 and a two-hundred day moving average of $7.34.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The company had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. During the same period in the prior year, the company posted ($0.59) EPS. Equities research analysts anticipate that Voyager Therapeutics, Inc. will post -1.03 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on VYGR shares. Leerink Partners initiated coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target on the stock. StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 18th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. Wedbush lowered their target price on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $14.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Voyager Therapeutics has an average rating of “Buy” and an average target price of $17.00.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now owns 86,001 shares in the company, valued at $500,525.82. This trade represents a 6.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 4.53% of the company’s stock.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.